Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2019

View Archived Issues

Inhibition of cystine/glutamate antiporter system Xc- identified as a possible target for epilepsy

Risk assessment for long QT syndrome

Mapping microbial metabolites to GPCRs

Phase II data for unadjuvanted subvirion monovalent inactivated influenza H3N2v vaccine

Syros Pharmaceuticals presents new CDK7/cyclin H inhibitors

Novel M4 positive allosteric modulator with improved physicochemical properties and favorable PK

Elicio presents preclinical data for ELI-002 vaccine targeting KRAS-driven cancers

APOC1 as a novel diagnostic and prognostic biomarker for gastric cancer

ZL-0580: a novel BRD4-selective small molecule that suppresses HIV

89bio initiates phase Ib/IIa study of BIO89-100 for the treatment of NASH

DPS-2: A dual MEK/ERK and PI3K/AKT inhibitor developed for colorectal cancer

First patient dosed in phase Ib/IIa PREVAIL study of PRV-3279

Kala Pharmaceuticals receives FDA complete response letter for KPI-121 0.25%

TaiGen Biotechnology presents influenza cap-dependent endonuclease inhibitors

Immuron reports data from TREAT-003 study of IMM-124-E in severe alcoholic hepatitis

New selective estrogen receptor modulators disclosed by Radius Pharmaceuticals

Sesen Bio presents developmental update for Vicinium

NIH awards major grant to ImmunogenX to conduct phase II study for latiglutenase

Hemispherx reports positive safety and survival data from phase I study of Ampligen

New liver cell discovery may enable hepatic regeneration

Starpharma initiates phase I/II study of DEP irinotecan

Phase IIb/III THEIA-1 study of TOP-1630 does not meet primary endpoints

FDA accepts Agenus' AGEN-2373 IND filing

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...